These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 18710898)

  • 1. Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance.
    Kobelt G
    Rheumatology (Oxford); 2008 Oct; 47(10):1589-90; author reply 1590; discussion 1590-1. PubMed ID: 18710898
    [No Abstract]   [Full Text] [Related]  

  • 2. Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance.
    Wailoo A; Bansback N; Chilcott J
    Rheumatology (Oxford); 2008 Feb; 47(2):119-20. PubMed ID: 18208819
    [No Abstract]   [Full Text] [Related]  

  • 3. [Anti-TNF alfa therapy in ankylosing spondylitis].
    Cravo AR; Tavares V; Da Silva JC
    Acta Med Port; 2006; 19(2):141-50. PubMed ID: 17187716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice.
    Elewaut D; Matucci-Cerinic M
    Rheumatology (Oxford); 2009 Sep; 48(9):1029-35. PubMed ID: 19561158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice.
    Escudero-Vilaplana V; Ramírez-Herráiz E; Alañón-Plaza E; Trovato-López N; García-Vicuña R; Carreño-Pérez L; Morell-Baladrón A; Sanjurjo-Sáez M
    Int J Clin Pharm; 2015 Oct; 37(5):808-14. PubMed ID: 25910480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of tumor necrosis factor alpha and ankylosing spondylitis.
    Marzo-Ortega H; Emery P; McGonagle D
    N Engl J Med; 2003 Jan; 348(4):359-61; author reply 359-61. PubMed ID: 12542065
    [No Abstract]   [Full Text] [Related]  

  • 7. Tumor necrosis factor-alpha blockade in ankylosing spondylitis: a potent but expensive anti-inflammatory treatment or true disease modification?
    Van den Bosch F; De Keyser F; Mielants H; Veys EM
    Arthritis Res Ther; 2005; 7(3):121-3. PubMed ID: 15899063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour necrosis factor inhibitors in ankylosing spondylitis.
    Reed MR; Taylor AL
    Intern Med J; 2008 Oct; 38(10):781-9. PubMed ID: 18422565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in Germany.
    Neilson AR; Sieper J; Deeg M
    Rheumatology (Oxford); 2010 Nov; 49(11):2122-34. PubMed ID: 20660498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The treatment of ankylosing spondylitis.
    Scalapino KJ; Davis JC
    Clin Exp Med; 2003 Feb; 2(4):159-65. PubMed ID: 12624705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis.
    Escalas C; Trijau S; Dougados M
    Rheumatology (Oxford); 2010 Jul; 49(7):1317-25. PubMed ID: 20360041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alopecia areata during etanercept therapy.
    Pan Y; Rao NA
    Ocul Immunol Inflamm; 2009; 17(2):127-9. PubMed ID: 19412875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are there new emerging drugs for ankylosing spondylitis or spondyloarthritis?
    Wendling D
    Expert Opin Emerg Drugs; 2013 Mar; 18(1):5-7. PubMed ID: 23216081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumour necrosis factor therapy for ankylosing spondylitis--unresolved issues.
    Jois RN; Gaffney K; Keat A
    Rheumatology (Oxford); 2007 Jun; 46(6):899-901. PubMed ID: 17308313
    [No Abstract]   [Full Text] [Related]  

  • 15. BSR guidelines for TNF blockers in ankylosing spondylitis--how useful are they?
    Sheehy C; Murphy E; Barry M
    Rheumatology (Oxford); 2006 Sep; 45(9):1176-7; author reply 1177-8. PubMed ID: 16820380
    [No Abstract]   [Full Text] [Related]  

  • 16. Paradoxical psoriasis following anti-TNF therapy in ankylosing spondylitis: A population-based cohort study.
    Bae JM; Kwon HS; Kim GM; Park KS; Kim KJ
    J Allergy Clin Immunol; 2018 Sep; 142(3):1001-1003.e2. PubMed ID: 29859201
    [No Abstract]   [Full Text] [Related]  

  • 17. The impact of the NICE appraisal consultation document on anti-TNF therapy for ankylosing spondylitis.
    Smith N; Gadsby K; Butt S; Deighton C
    Rheumatology (Oxford); 2007 Jun; 46(6):1044-5. PubMed ID: 17401132
    [No Abstract]   [Full Text] [Related]  

  • 18. Central nervous system Aspergillus fumigatus presenting as cranial nerve palsy in a patient with ankylosing spondylitis on anti-TNF therapy.
    Slusher JR; Maldonado ME; Mousavi F; Lozada CJ
    Rheumatology (Oxford); 2008 May; 47(5):739-40. PubMed ID: 18381385
    [No Abstract]   [Full Text] [Related]  

  • 19. Can structural damage be prevented in ankylosing spondylitis?
    Sieper J
    Curr Opin Rheumatol; 2009 Jul; 21(4):335-9. PubMed ID: 19424070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Main symptom: chronic deep back pain. Do you know the signs of Bechterew disease?].
    MMW Fortschr Med; 2007 Jan; 149(4):13. PubMed ID: 17615709
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.